|
9 Companies |
|
15 Products |
|
15 Products |
|
26 Mechanisms of Action |
|
4 Trials |
|
181 News |
|
| 1234» |
- Biomarker, Trial completion, Enrollment change, BRCA Biomarker: Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer (clinicaltrials.gov) - Sep 9, 2019
P=N/A, N=17, Completed, Sponsor: University of Washington
Active, not recruiting --> Completed | N=30 --> 17
- Biomarker, Enrollment open, BRCA Biomarker: S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer (clinicaltrials.gov) - Sep 9, 2019
P2b, N=200, Recruiting, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed | N=30 --> 17 Not yet recruiting --> Recruiting
- | Venofer (iron sucrose complex) / Daiichi Sankyo, CSL Behring
Phase classification, Enrollment change, Trial withdrawal: Sentinel Lymph Node Identification in the Axilla of Women With Breast Cancer Using Ultrasound and Iron Injection (clinicaltrials.gov) - Mar 26, 2019
P1, N=0, Withdrawn, Sponsor: Columbia University
Not yet recruiting --> Recruiting Phase classification: P=N/A --> P1 | N=20 --> 0 | Recruiting --> Withdrawn
- | tamoxifen / Generic mfg.
Biomarker, Trial completion: Effect of Pharmacogenomics Differences in Phase I and II Metabolism of Tamoxifen on Efficacy and Toxicity (clinicaltrials.gov) - Mar 14, 2019
P1, N=41, Completed, Sponsor: Milton S. Hershey Medical Center
Phase classification: P=N/A --> P1 | N=20 --> 0 | Recruiting --> Withdrawn Active, not recruiting --> Completed
- Enrollment change: Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer (clinicaltrials.gov) - Jan 31, 2019
P2, N=0, Withdrawn, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed N=25 --> 0
- | NN1213 / Novo Nordisk
Biomarker, Enrollment change, Trial withdrawal: Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors (clinicaltrials.gov) - Jan 18, 2019
P1/2, N=0, Withdrawn, Sponsor: Eli Avisar
N=25 --> 0 N=44 --> 0 | Suspended --> Withdrawn
- | Biomarker, Trial completion: Studying Biomarkers in Nipple Fluid, Urine, and Blood Samples From Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer and in Women at Risk of Developing Breast Cancer (clinicaltrials.gov) - Oct 5, 2018
P=N/A, N=316, Completed, Sponsor: Mayo Clinic
N=44 --> 0 | Suspended --> Withdrawn Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Effects of Diet and Exercise on Ductal Carcinoma in Situ (clinicaltrials.gov) - Aug 31, 2018
P=N/A, N=32, Completed, Sponsor: University of Alabama at Birmingham
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors (clinicaltrials.gov) - Aug 9, 2018
P2, N=52, Completed, Sponsor: Ohio State University Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Phase classification, Surgery: RAPID: Randomized Trial of Accelerated Partial Breast Irradiation (clinicaltrials.gov) - Jul 13, 2018
P=N/A, N=2135, Completed, Sponsor: Ontario Clinical Oncology Group (OCOG)
Active, not recruiting --> Completed Phase classification: P3 --> P=N/A
- | NN1213 / Novo Nordisk
Biomarker, Trial completion date, Trial suspension, Trial primary completion date: Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors (clinicaltrials.gov) - Jun 14, 2018
P1/2, N=44, Suspended, Sponsor: Eli Avisar
Phase classification: P3 --> P=N/A Trial completion date: Jul 2023 --> Jan 2024 | Recruiting --> Suspended | Trial primary completion date: Jul 2022 --> Jan 2023
- | Trial completion, Trial completion date, Trial primary completion date, Surgery: RAPID: Randomized Trial of Accelerated Partial Breast Irradiation (clinicaltrials.gov) - Apr 6, 2018
P3, N=2128, Completed, Sponsor: Ontario Clinical Oncology Group (OCOG)
Trial completion date: Jul 2023 --> Jan 2024 | Recruiting --> Suspended | Trial primary completion date: Jul 2022 --> Jan 2023 Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Mar 2018 | Trial primary completion date: Jun 2020 --> Mar 2018
- | letrozole / Generic mfg.
Trial completion: DCIS: Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ (clinicaltrials.gov) - Mar 27, 2018
P2, N=108, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Mar 2018 | Trial primary completion date: Jun 2020 --> Mar 2018 Active, not recruiting --> Completed
- | Trial completion date, Trial primary completion date: Effects of Diet and Exercise on Ductal Carcinoma in Situ (clinicaltrials.gov) - Mar 19, 2018
P=N/A, N=32, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Active, not recruiting --> Completed Trial completion date: Dec 2017 --> Jul 2018 | Trial primary completion date: Dec 2017 --> Jul 2018
- | Biomarker, Trial completion date, Trial initiation date, Trial primary completion date: Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors (clinicaltrials.gov) - Feb 22, 2018
P1/2, N=44, Recruiting, Sponsor: Eli Avisar
Trial completion date: Dec 2017 --> Jul 2018 | Trial primary completion date: Dec 2017 --> Jul 2018 Initiation date: Dec 2017 --> Jul 2018 | Trial primary completion date: Dec 2021 --> Jul 2022 | Trial completion date: Dec 2022 --> Jul 2023
- | Biomarker, Trial primary completion date: Studying Biomarkers in Nipple Fluid, Urine, and Blood Samples From Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer and in Women at Risk of Developing Breast Cancer (clinicaltrials.gov) - Feb 6, 2018
P=N/A, N=300, Active, not recruiting, Sponsor: Mayo Clinic
Initiation date: Dec 2017 --> Jul 2018 | Trial primary completion date: Dec 2021 --> Jul 2022 | Trial completion date: Dec 2022 --> Jul 2023 Trial primary completion date: Sep 2017 --> Sep 2018
- | Biomarker, Trial completion, BRCA Biomarker: S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer (clinicaltrials.gov) - Nov 24, 2017
P2b, N=208, Completed, Sponsor: Southwest Oncology Group
Trial primary completion date: Sep 2017 --> Sep 2018 Active, not recruiting --> Completed
- | ritonavir / Generic mfg.
Biomarker, Trial completion, Enrollment change: Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer (clinicaltrials.gov) - Oct 25, 2017
P1/2, N=28, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=52 --> 28
- | Signifor (pasireotide) / Recordati
Phase classification, Enrollment change, Trial termination: Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor (clinicaltrials.gov) - Aug 14, 2017
P1/2, N=7, Terminated, Sponsor: New York University School of Medicine
Phase classification: P2 --> P1/2 | N=12 --> 7 | Completed --> Terminated; PI has passed away. Requested by department to terminate study.
- | Biomarker, Enrollment open: Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors (clinicaltrials.gov) - Aug 10, 2017
P1/2, N=44, Recruiting, Sponsor: Eli Avisar
Requested by department to terminate study. Not yet recruiting --> Recruiting
- | Zolinza (vorinostat) / Merck (MSD)
Trial completion, Trial primary completion date: Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast (clinicaltrials.gov) - Aug 7, 2017
P1, N=17, Completed, Sponsor: University of California, San Francisco
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Jul 2011 --> Nov 2011
- | Soltamox (tamoxifen citrate) / Jazz
Trial primary completion date: Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen (clinicaltrials.gov) - Aug 1, 2017
P2, N=501, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
Active, not recruiting --> Completed | Trial primary completion date: Jul 2011 --> Nov 2011 Trial primary completion date: Mar 2010 --> Sep 2010
- | Trial primary completion date: Effects of Diet and Exercise on Ductal Carcinoma in Situ (clinicaltrials.gov) - Jul 19, 2017
P=N/A, N=32, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Trial primary completion date: Mar 2010 --> Sep 2010 Trial primary completion date: Jun 2017 --> Dec 2017
- | letrozole / Generic mfg.
Trial primary completion date: DCIS: Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ (clinicaltrials.gov) - Jul 13, 2017
P2, N=108, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Jun 2017 --> Dec 2017 Trial primary completion date: Jun 2017 --> Aug 2016
- | Phase classification: Targeted Intra-Operative Radiotherapy for the Management of Ductal Carcinoma In-Situ of the Breast (clinicaltrials.gov) - Jul 11, 2017
P=N/A, N=22, Terminated, Sponsor: University of Southern California
Trial primary completion date: Jun 2017 --> Aug 2016 Phase classification: P2 --> P=N/A
- | Soltamox (tamoxifen citrate) / Jazz
Trial completion, Phase classification: Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen (clinicaltrials.gov) - Jul 2, 2017
P2, N=501, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
Phase classification: P2 --> P=N/A Active, not recruiting --> Completed | Phase classification: PN/A --> P2
- | letrozole / Generic mfg.
Trial completion: WISE: Letrozole in Preventing Breast Cancer in Postmenopausal Women (clinicaltrials.gov) - Jun 28, 2017
P2, N=49, Completed, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed | Phase classification: PN/A --> P2 Recruiting --> Completed
- | Trial completion: Pain After Tumescent Mastectomy or Standard Mastectomy in Women With Stage I, Stage II, or Stage III Breast Cancer (clinicaltrials.gov) - Jun 21, 2017
P=N/A, N=74, Completed, Sponsor: University of California, Davis
Recruiting --> Completed Recruiting --> Completed
- ||| Trial completion: NASSM: Study to Assess Perfusion and Patient Satisfaction in Nipple-Areola Mastectomy With Immediate Reconstruction (clinicaltrials.gov) - Jun 16, 2017
P=N/A, N=83, Completed, Sponsor: Washington University School of Medicine
Recruiting --> Completed Active, not recruiting --> Completed
- | Biomarker, Trial initiation date, Trial primary completion date: Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors (clinicaltrials.gov) - Jun 9, 2017
P1/2, N=44, Not yet recruiting, Sponsor: Eli Avisar
Active, not recruiting --> Completed Initiation date: May 2017 --> Dec 2017 | Trial primary completion date: May 2021 --> Dec 2021
- | Biomarker, Trial primary completion date, BRCA Biomarker: S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer (clinicaltrials.gov) - Jun 2, 2017
P2b, N=200, Active, not recruiting, Sponsor: Southwest Oncology Group
Initiation date: May 2017 --> Dec 2017 | Trial primary completion date: May 2021 --> Dec 2021 Trial primary completion date: Apr 2017 --> Jul 2017
- | Biomarker, Trial completion, Trial primary completion date: Biomarkers in Tissue Samples From Patients With Ductal Breast Carcinoma in Situ (clinicaltrials.gov) - May 17, 2017
P=N/A, N=500, Completed, Sponsor: ECOG-ACRIN Cancer Research Group
Trial primary completion date: Apr 2017 --> Jul 2017 Not yet recruiting --> Completed | Trial primary completion date: Apr 2011 --> Apr 2010
- | Trial completion, Enrollment change, Trial primary completion date: BCCR: Breast Cancer Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer (clinicaltrials.gov) - May 15, 2017
P=N/A, N=4945, Completed, Sponsor: University of Nebraska
Not yet recruiting --> Completed | Trial primary completion date: Apr 2011 --> Apr 2010 Recruiting --> Completed | N=999999 --> 4945 | Trial primary completion date: Dec 2020 --> Dec 2016
- | Trial completion, Trial primary completion date: Molecular Breast Imaging (MBI) in Patients With Suspected Ductal Carcinoma in Situ (DCIS) (clinicaltrials.gov) - Mar 22, 2017
P=N/A, N=200, Completed, Sponsor: Mayo Clinic
Recruiting --> Completed | N=999999 --> 4945 | Trial primary completion date: Dec 2020 --> Dec 2016 Enrolling by invitation --> Completed | Trial primary completion date: Dec 2016 --> Nov 2014
- | Trial completion, Enrollment change, Trial primary completion date, Surgery: Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery (clinicaltrials.gov) - Mar 22, 2017
P1, N=27, Completed, Sponsor: Avelas Biosciences, Inc.
Enrolling by invitation --> Completed | Trial primary completion date: Dec 2016 --> Nov 2014 Recruiting --> Completed | N=39 --> 27 | Trial primary completion date: Jul 2016 --> Jan 2017
- | Enrollment change, IO biomarker, Surgery: Studying Cells Collected Through Ductal Lavage in Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast Cancer (clinicaltrials.gov) - Mar 15, 2017
P=N/A, N=30, Completed, Sponsor: Wake Forest University Health Sciences
Recruiting --> Completed | N=39 --> 27 | Trial primary completion date: Jul 2016 --> Jan 2017 N=70 --> 30
- | Trial completion, Trial primary completion date: A Pilot Pre-operative Window Trial of Black Cohosh in Women With Ductal Carcinoma in Situ (clinicaltrials.gov) - Feb 28, 2017
P=N/A, N=33, Completed, Sponsor: Yale University
N=70 --> 30 Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Jan 2016
- | Biomarker, Trial primary completion date, BRCA Biomarker: S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer (clinicaltrials.gov) - Feb 27, 2017
P2b, N=200, Active, not recruiting, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Jan 2016 Trial primary completion date: Jan 2017 --> Apr 2017
- ||| Trial completion, Trial primary completion date, MRI: Digital Breast Tomosynthesis Versus Contrast Enhanced Magnetic Resonance Imaging (MRI) for Breast Cancer Staging (clinicaltrials.gov) - Feb 23, 2017
P=N/A, N=51, Completed, Sponsor: Dartmouth-Hitchcock Medical Center
Trial primary completion date: Jan 2017 --> Apr 2017 Active, not recruiting --> Completed | Trial primary completion date: Aug 2016 --> Dec 2016
- tamoxifen / Generic mfg.
Biomarker, Enrollment closed: Effect of Pharmacogenomics Differences in Phase I and II Metabolism of Tamoxifen on Efficacy and Toxicity (clinicaltrials.gov) - Jan 30, 2017
P1, N=41, Active, not recruiting, Sponsor: Milton S. Hershey Medical Center
Active, not recruiting --> Completed | Trial primary completion date: Aug 2016 --> Dec 2016 Suspended --> Active, not recruiting
- Trial primary completion date: Effects of Diet and Exercise on Ductal Carcinoma in Situ (clinicaltrials.gov) - Jan 19, 2017
P=N/A, N=32, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Suspended --> Active, not recruiting Trial primary completion date: Dec 2016 --> Jun 2017
- Enrollment change, Trial termination: CK-SAPBI: CyberKnife Stereotactic Accelerated Partial Breast Irradiation (SAPBI) (clinicaltrials.gov) - Jan 19, 2017
P1/2, N=2, Terminated, Sponsor: Georgetown University
Trial primary completion date: Dec 2016 --> Jun 2017 N=10 --> 2 | Recruiting --> Terminated; Slow accrual
- arzoxifene (LY353381) / Eli Lilly
Trial completion: Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer (clinicaltrials.gov) - Jan 13, 2017
P1, N=0, Completed, Sponsor: University of Kansas Medical Center
N=10 --> 2 | Recruiting --> Terminated; Slow accrual Active, not recruiting --> Completed
- Biomarker, Trial initiation date, Trial primary completion date: Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors (clinicaltrials.gov) - Jan 6, 2017
P1/2, N=44, Not yet recruiting, Sponsor: Eli Avisar
Active, not recruiting --> Completed Initiation date: Oct 2016 --> Apr 2017 | Trial primary completion date: Oct 2020 --> Apr 2021
- | New P2 trial, Surgery: Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast (clinicaltrials.gov) - Dec 27, 2016
P2, N=224, Completed, Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Biomarker, Trial primary completion date: Studying Biomarkers in Nipple Fluid, Urine, and Blood Samples From Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer and in Women at Risk of Developing Breast Cancer (clinicaltrials.gov) - Dec 21, 2016
P=N/A, N=300, Active, not recruiting, Sponsor: Mayo Clinic
Initiation date: Oct 2016 --> Apr 2017 | Trial primary completion date: Oct 2020 --> Apr 2021 Trial primary completion date: Sep 2016 --> Sep 2017
- ||| Enrollment open: A Registry Study of Breast Microseed Treatment (clinicaltrials.gov) - Dec 14, 2016
P=N/A, N=420, Recruiting, Sponsor: Concure Oncology-Breast Microseed Inc.
Trial primary completion date: Sep 2016 --> Sep 2017 Not yet recruiting --> Recruiting
- Biomarker, Trial primary completion date, BRCA Biomarker: S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer (clinicaltrials.gov) - Nov 15, 2016
P2b, N=200, Active, not recruiting, Sponsor: Southwest Oncology Group
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2015 --> Jan 2017
- Enrollment closed, Enrollment change: Effects of Diet and Exercise on Ductal Carcinoma in Situ (clinicaltrials.gov) - Nov 15, 2016
P=N/A, N=32, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Trial primary completion date: Sep 2015 --> Jan 2017 Recruiting --> Active, not recruiting | N=40 --> 32
- Biomarker, New P1/2 trial: Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors (clinicaltrials.gov) - Aug 5, 2016
P1/2, N=44, Not yet recruiting, Sponsor: Eli Avisar